secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001819790-23-000081
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus reports Q3 net loss $39.1M; XDEMVY launch yields $1.7M in 5 weeks
------------------------------------------------------------------------

- Net product sales of XDEMVY were $1.7M with ~1,700 bottles dispensed in first 5 weeks post-launch.
- Net loss of $39.1M ($1.28 per share) vs. $22.5M loss ($0.84) in Q3 2022; SG&A rose to $30.3M on launch costs.
- Gross-to-net discount on XDEMVY was 73%, better than anticipated; cash, equivalents and marketable securities $246.9M.
- Received $99.4M net proceeds from August 2023 public equity offering; balance sheet strengthened.
- XDEMVY added to AAO Preferred Practice Pattern guidelines as first FDA-approved therapy for Demodex blepharitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/0001819790-23-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/tars-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001819790-23-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer